Abstract
Importance of the field: The receptor CRTH2 (also known as DP2) is an important mediator of the inflammatory effects of prostaglandin D 2 and has attracted much attention as a therapeutic target for the treatment of conditions such as asthma, COPD, allergic rhinitis and atopic dermatitis. Areas covered in this review: The validation of CRTH2 as a therapeutic target and the early antagonists are summarized, CRTH2 antagonists published in the patent literature from 2006 to 2009 are comprehensively covered and a general update on the recent progress in the development of CRTH2 antagonists for the treatment of inflammatory diseases is provided. What the reader will gain: Insight into the validation of CRTH2 as a therapeutic target, a comprehensive overview of the development of new CRTH2 ligands between 2006 and 2009, and a general overview of the state of the art. Take home message: Many diverse potent CRTH2 antagonists are now available, and several are in or on the way into the clinic. It is still early to draw final conclusions, but preliminary results give reason for optimism, and the prospect that we will see new CRTH2 antagonists reaching the market for the treatment of asthma, rhinitis, atopic dermatitis and/or COPD seems good.
| Original language | English |
|---|---|
| Journal | Expert Opinion on Therapeutic Patents |
| Volume | 20 |
| Issue number | 11 |
| Pages (from-to) | 1505-1530 |
| Number of pages | 26 |
| ISSN | 1354-3776 |
| DOIs | |
| Publication status | Published - 1 Nov 2010 |